Cabaletta Bio (CABA) Net Cash Flow (2018 - 2025)
Cabaletta Bio (CABA) posted quarterly Net Cash Flow of $22.8 million for Q4 2025, up 443.86% year-over-year from $4.2 million in Q4 2024, and up 126.68% quarter-over-quarter from -$85.4 million in Q3 2025.
Cabaletta Bio (CABA) Net Cash Flow (2018 - 2025) Analysis & Trends
Cabaletta Bio's Net Cash Flow history runs 8 years deep, the most recent figure standing at $22.8 million for Q4 2025.
- In Q4 2025, Net Cash Flow rose 443.86% year-over-year to $22.8 million; the TTM figure through Dec 2025 stood at -$81.0 million (down 176.86% YoY), while the FY2025 annual figure was -$81.0 million, down 176.86% from the prior year.
- Net Cash Flow for Q4 2025 stood at $22.8 million, up from -$85.4 million in the prior quarter.
- The five-year high for Net Cash Flow was $77.7 million in Q4 2023, with the low at -$85.4 million in Q3 2025.
- The 5-year median for Net Cash Flow is $2.8 million (2021), against an average of -$922300.0.
- The sharpest annual moves came in 2021 and 2022: Net Cash Flow soared 649.01% in 2021, then sank 1409.37% in 2022.
- Cabaletta Bio's Net Cash Flow stood at $4.0 million in 2021, then surged by 416.0% to $20.4 million in 2022, then jumped by 280.24% to $77.7 million in 2023, then tumbled by 108.52% to -$6.6 million in 2024, then jumped by 443.86% to $22.8 million in 2025.
- Business Quant data shows CABA's Net Cash Flow at $22.8 million in Q4 2025, -$85.4 million in Q3 2025, and $13.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Cabaletta Bio | 466.25 Mn | 466.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 22.78 Mn |
| Dec 31, 2025 | 22.78 Mn |
| Sep 30, 2025 | -85.40 Mn |
| Sep 30, 2025 | -85.40 Mn |
| Jun 30, 2025 | 13.75 Mn |
| Jun 30, 2025 | 13.75 Mn |
| Mar 31, 2025 | -32.14 Mn |
| Mar 31, 2025 | -32.14 Mn |
| Dec 31, 2024 | -6.63 Mn |
| Dec 31, 2024 | -6.63 Mn |
| Sep 30, 2024 | -8.01 Mn |
| Sep 30, 2024 | -8.01 Mn |
| Jun 30, 2024 | 3.32 Mn |
| Jun 30, 2024 | 3.32 Mn |
| Mar 31, 2024 | -17.95 Mn |
| Mar 31, 2024 | -17.95 Mn |
| Dec 31, 2023 | 77.74 Mn |
| Dec 31, 2023 | 77.74 Mn |
| Sep 30, 2023 | -12.57 Mn |
| Sep 30, 2023 | -12.57 Mn |